Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arca Biopharma Inc (ABIO)

Arca Biopharma Inc (ABIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Arca Biopharma Inc 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 USA

www.arcabio.com P: 720-940-2200

Description:

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products. The Company's business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.

Key Statistics

Overview:

Market Capitalization, $K 48,163
Enterprise Value, $K 10,733
Shares Outstanding, K 14,507
Annual Sales, $ 0 K
Annual Net Income, $ -5,340 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -2,010 K
EBIT, $ -7,980 K
EBITDA, $ -7,870 K
60-Month Beta 0.97
% of Insider Shareholders 30.90%
% of Institutional Shareholders 56.44%
Float, K 10,024
% Float 69.10%
Short Volume Ratio 0.48

Growth:

1-Year Return 62.25%
3-Year Return -8.31%
5-Year Return -48.76%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 96.39%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.14 on 04/25/24
Next Earnings Date 07/19/24
Earnings Per Share ttm -0.42
EPS Growth vs. Prev Qtr -75.00%
EPS Growth vs. Prev Year -55.56%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-18 on 04/04/19

ABIO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -16.07%
Return-on-Assets % -15.51%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 1.38
Book Value/Share 2.42
Interest Coverage -0.15
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar